linjc16/ctgov huggingface dataset:
Comparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function

Study Overview
=================
Brief Summary
-----------------
Assess the values of train-of-four ratios with the TetraGraph and thoses obtained with the TOFscan during recovery of neuromusculat function in surgical patients who have been administred rocuronium. Primary outcome : value of TOFratio with the TetraGraph when TOFratio of TOFscan is greater than or equal to 90% Pilot study : no hypothesis

Official Title
-----------------
Comparison of the TOFscan and the TetraGraph During Recovery of Neuromuscular Function : a Pilot Study

Conditions
-----------------
Neuromuscular Blockade

Intervention / Treatment
-----------------
* Device: TetraGraph


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age greater than or equal to 18 years old patients willing to participate and provide an informed consent elective surgical procedures, without emergency, administration of rocuronium for neuromuscular blockade, and recovery of complete neuromuscular function at the end of the surgery Exclusion Criteria: patients with unilateral disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or similar wrist injury patients with systemic neuromuscular diseases such as myasthenia gravis renal insufficiency or renal failure significant liver disease patients having surgery that would involve prepping the arm into the sterile field allergy to rocuronium

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: TetraGraph|Use of two monitoring devices of neuromuscular function during surgery|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Train-of-four ratios | Value of TOFratio with TetraGraph when TOFratio with TOFscan is greater than or equal to 90% (first value of three greater than or equal to 90%) | baseline (J0) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Train-of-four ratios | Value of TOFratio with TetraGraph when TOFratio with TOFscan is greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and eventually 100% | baseline (J0) | 
| Train-of-four ratios | Value of TOFratio with TOFscan when TOFratio with TetraGraph is greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% and eventually 100% | baseline (J0) | 
| Train-of-four count | Time to recover one, two, three and four responses from TOFcount with TOFscan and TetraGraph | baseline (J0) |
Nebula Study - Screener Apps and HSAT vs. PSG Comparison

Study Overview
=================
Brief Summary
-----------------
This is a prospective, unblinded, open-label, single group study. All subjects will undergo concurrent screener app, HSAT testing, and in-lab polysomnography.

Official Title
-----------------
Nebula Study: Comparison of Sleep Screener Apps and Home Sleep Apnea Tests to Polysomnography

Conditions
-----------------
Sleep Apnea, Obstructive

Intervention / Treatment
-----------------
* Diagnostic Test: PSG
* Diagnostic Test: Home Sleep Apnea Test with FDA cleared devices
* Other: Non-Contact Screening App


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant is 18 years of age or older Participant is willing to provide informed consent Participant is willing to participate in all study related procedures Exclusion Criteria: Unable to cease PAP therapy during PSG (if currently using) Requires use of oxygen therapy during sleep Diagnosis of untreated clinically relevant sleep disorder (other than SDB) Pregnant Participant is unsuitable to participate in the study in the opinion of the investigator Participant has a permanent pacemaker, sustained non-sinus cardiac arrhythmias, and/or takes alpha blocker or short acting nitrate medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Concurrent PSG, HSAT, and Screener App Test<br>Participants will undergo a single night baseline PSG test with concurrent HSAT tests as well as non-contact screening mobile apps through a smartphone. | Diagnostic Test: PSG<br>* In-lab sleep polysomnography test<br>Diagnostic Test: Home Sleep Apnea Test with FDA cleared devices<br>* In-lab HST test<br>Other: Non-Contact Screening App<br>* Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AHI value. Clinical decision for treatment output (Y to CPAP or N to CPAP) of Screener apps and HSAT compared to PSG. | The PSG clinical decision for treatment is defined as AHI≥15. Screener apps and HSATs provide AHI values that will be used for comparison. | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OSA severity categories (normal, mild, moderate, severe) of Screnner apps and HSAT compared to PSG. |  | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OSA, Sleep Apnea, OSA Screeners, Home Sleep Apnea Test
Preoperative Survey

Study Overview
=================
Brief Summary
-----------------
This study will examine preoperative concerns in older adults through the use of a self-administered questionnaire. The development of this questionnaire will involve adapting survey questions from previously validated studies, creating new questions, and generating a comprehensive questionnaire.

Detailed Description
-----------------
The primary objective is to assess the preoperative concerns in older adults. This objective will be assessed by using a self-administered questionnaire. The secondary objective is to examine older adults' attitudes toward preoperative cognitive assessments, functional assessments, and prehabilitation programs. Similarly, this objective will be assessed by using a self-administered questionnaire. Survey administration will be completed online and in person. Recruited participants will receive an email that contains an external link to the online version of the survey that will be administered on Research Electronic Data Capture (REDCap), an online platform to complete secure surveys. Once received, participants will be able to anonymously complete the survey and not have to provide any identification information except for general sociodemographic variables. Alternatively, study personnel will administer the questionnaire on an iPad in person at the preoperative clinic to assess surgical population and geriatric clinic to assess medical population at Mount Sinai Hospital.

Official Title
-----------------
Preoperative Concerns in Older Adults

Conditions
-----------------
Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older adults, who are aged 65 or older and Medical patients in geriatric clinic or surgical inpatients in pre-operative clinics Exclusion Criteria: • Lack English language capability

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preoperative concerns | current daily functional status | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive assessments | Administration of cognitive status questionnaire | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Elderly, surgical
Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy

Study Overview
=================
Brief Summary
-----------------
This study will compare the effect of two topical non-steroidal antiinflammatory agents to control pain after photorefractive keratectomy (PRK) eye surgery.

Official Title
-----------------
Bromday (Bromfenac Ophthalmic Solution)0.09% QD vs Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Control of Pain and Epithelial Healing Post (PRK)

Conditions
-----------------
Myopia

Intervention / Treatment
-----------------
* Drug: Bromfenac


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male or female at least 18 years of age, no other ocular studies with 15 days prior to dosing, BCVA 20/200 or better, return for study visits and follow instructions from investigator and staff, self administer test article Exclusion Criteria: Ocular inflammation, hypersensitivity to bromfenac or nepafenac, any corneal pathology, have had radial keratotomy, corneal transplant or corneal refractive surgery in the last two years

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Nepafenac<br> | Drug: Bromfenac<br>* Bromfenac 0.09% 1 drop in study eyes q day<br>* Other names: Bromday;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-PRK pain |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-PRK epithelial healing |  | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PRK, bromfenac, nepafenac, epithelial healing,
Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

Study Overview
=================
Brief Summary
-----------------
This project aims to document and analyse - with a three-fold anthropological, psychosocial and economical approach - the consequences of the geographical distance from mainland France on the alloSCT on both patients, their caregivers and the healthcare system. It is organised in 3 working packages (WP).

Official Title
-----------------
Impact of the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Reunion Island Patients: Quality of Life, Determinants of Choices and Financial Repercussions

Conditions
-----------------
Allogeneic Hematopoietic Stem Cell Transplantation

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with hematological malignancy (myeloid acute leukemia, lymphoid acute leukemia, non-hodgkin lymphoma, Hodgkin disease, or myelodysplasic syndrome candidate to an allogeneic hematopoietic stem cell transplantation in mainland France ; Residing in Reunion Island Age >18 year old; who accept or not allogeneic hematopoietic Able to complete a questionnaire Exclusion Criteria: Opposition to participation and collection of their data Person deprived of liberty by judicial or administrative decision, and person subject to legal protection (guardianship or curators)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients who accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)<br> | Other: questionnaire<br>* quality of life score: FACT-BMT decisional conflict scale Discreet Choice Experiment questionnaire<br>|
| patients who did not accept Allogeneic Hematopoietic Stem Cell Transplantation (alloH SCT)<br> | Other: questionnaire<br>* quality of life score: FACT-BMT decisional conflict scale Discreet Choice Experiment questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life Functional Assessment of Cancer Therapy - Bone Marrow Transplantation questionnaire. (FACT-BMT questionnaire) |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| satisfaction with decision questionnaire |  | 24 months | 
| decision regret scale |  | 24 months | 
| fear of recurrence questionnaire |  | 24 months | 
| preferences of patients questionnaire |  | 24 months | 
| cost of treatment | impact on patients and caregivers; impact on society | 24 months |
Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in Europe. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different premixed insulin analogues given in combination with an oral anti-diabetic drug.

Official Title
-----------------
Comparison of the Effect on Glycemic Control of Biphasic Insulin Aspart 70/30, Biphasic Insulin Aspart 50/50, and Biphasic Insulin Aspart 30/70 All in Combination With Metformin in Subjects With Type 2 Diabetes (the INTENSIMIX Trial).

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: biphasic insulin aspart
* Drug: metformin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 diabetes Currently treated with insulin Currently treated with Metformin HbA1c: 7.5-12.0% Exclusion Criteria: Body Mass Index (BMI) < 25.0 or > 40.0 kg/m2 Metformin contraindications according to local practice TZDs within 6 months prior to randomisation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: biphasic insulin aspart|nan|
|Drug: metformin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 36 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 8-point plasma glucose profiles |  |  | 
| Safety variables |  |  | 
| Other glycemic variables |  |  |
Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen

Study Overview
=================
Brief Summary
-----------------
The recurrence of endometriosis after surgery a formidable challenge for the gynecologist. Recurrence rates reported in the literature are very high, being 21.5% at 2 years and 40-50% at 5 years. Several theories attempt to explain these high figures. The three most widely accepted are: The presence of residual endometriotic tissue or residual endometriotic cells not completely eradicated during surgery The growth of undetected microscopic endometriosis during surgery The development of endometriotic lesions de novo Patients with symptomatic endometriosis diagnosed by ultrasound or MRI and suitable for surgery will participate in the study. The surgical specimens sent for pathology from bladder, vagina, uterosacral, sigma or rectum will be properly marked for studying the presence of endometriosis.

Detailed Description
-----------------
Patients of Dexeus Universitary Institute that are having a laparoscopic surgery for deep endometriosis will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study. Only three expert surgeons of the Gynecological Department of Dexeus Universitary Institute will participate in the study.

Official Title
-----------------
Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen

Conditions
-----------------
Deep Endometriosis, Recurrences, Margins in the Specimen, Laparoscopy, Prognosis Factors

Intervention / Treatment
-----------------
* Procedure: laparoscopic surgery for deep endometriosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with symptomatic endometriosis superior to 6 in a visual scale (VAS; Huskisson, 1974)diagnosed by ultrasound or MRI and suitable for laparoscopic surgery Exclusion Criteria: previous surgeries for deep endometriosis Non complete surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with symptomatic endometriosis<br> | Procedure: laparoscopic surgery for deep endometriosis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrences | Evaluate clinical recurrence rate of endometriosis after complete surgery | Two years after surgery |
Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions

Study Overview
=================
Brief Summary
-----------------
The purpose of this study, is to investigate the value of diffusion weighted imaging on the differential diagnosis of solitary pulmonary lesions.

Detailed Description
-----------------
When a patient is diagnosed with a lung lesion, the differential diagnosis is important, since the treatment is determined by the lesion character. The goal in the evaluation of solitary pulmonary lesions is to distinguish malignant lesions from benign lesions in as non-invasive a manner as possible. As computed tomography is widely used, the diagnosis of solitary pulmonary lesions has become easier. The size, features of the edges, shape, internal structure (calcification, fat content, cavitation, etc.), density, satellite nodule, growth rate and contrast involvement of the lesion are important properties which help to distinguish benign lesions from malignant ones. However, as the distinction is not absolute at all times, other imaging methods such as positron emission tomography and magnetic resonance are preferred. The importance of this issue is the high five-year survival rate in early-diagnosed lung cancer cases. Diffusion is the randomized microscopic motion of water molecules. It is known that diffusion is a sensitive parameter of tissue characterization at a microscopic level. Nowadays, diffusion is measured in vivo with diffusion weighted MRI and ADC measurements. Diffusion weighted imaging has a wide use on oncologic patients for the purpose of diagnosis. In addition, it is used in the distinction of acute cerebral infarction and epidermoid or arachnoid cysts. Recently, it has also been used in the characterization of cystic or solid lesions in the thoracic cavity. In this study, the investigators aimed to evaluate the accuracy of differentiation of solitary pulmonary lesions.

Official Title
-----------------
Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions

Conditions
-----------------
Thorax Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients had a solitary pulmonary nodule or mass. Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| On diffusion weighted images, the signal intensities of the lesions were visually compared to the SI of the thoracic spinal cord using a 5-point scale. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diffusion weighted magnetic resonance imaging